A phase III trial of GTL 001 against HPV 16/18 infections

Trial Profile

A phase III trial of GTL 001 against HPV 16/18 infections

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs GTL 001 (Primary)
  • Indications Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Sep 2016 According to a GENTICEL media release, a previous phase II study (Profile 700237810) did not show statistical difference in viral clearance between the treated group and the placebo group in the total population based on which the company has decided not make any further investment towards a phase III program of GTL-001.
    • 30 Sep 2016 Status changed from planning to withdrawn prior to enrolment, according to a GENTICEL media release.
    • 28 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top